Form 4: BioMarin Director Walbert Acquires Shares and Disposes of Indirect Holdings

Director Timothy P. Walbert reports acquisition of BioMarin Pharmaceutical Inc. shares through restricted stock units and disposal of indirect holdings.

Summary

• On May 20, 2025, Timothy P. Walbert, a director of BioMarin Pharmaceutical Inc., acquired 6,650 shares of common stock through the grant of restricted stock units at a price of $0.
• Following this transaction, Walbert directly owns 9,780 shares of BioMarin common stock.
• Walbert also indirectly owns 416 shares through Prairie Capital Ventures LLC, which were disposed of.
• The restricted stock units were granted on May 20, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it primarily reports transactions. The acquisition of shares is mildly positive, but the disposal of indirect holdings is mildly negative, balancing out the overall sentiment.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.

Negatives

• The disposal of indirectly held shares could be interpreted negatively, although the quantity is relatively small.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It's common for directors to receive stock-based compensation, aligning their interests with shareholders.

Stakeholder Impact

• Shareholders may view the director's stock acquisition as a positive sign of confidence in the company.

Key Dates

Keywords

BioMarin, Director, Walbert, Share Acquisition, Restricted Stock Units, Form 4, Beneficial Ownership, BMNR